Products
Online Inquiry
OSI-930
Cat. No.:
OB0125LY-079
Appearance:
Solid
Purity:
99.7%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
OSI-930 is a small molecule inhibitor with anti-tumor activity that primarily targets certain tyrosine kinases.
Synonym:
728033-96-3; OSI 930; OSI930; 3-( (Quinolin-4-ylmethyl)amino)-N-(4-(trifluoromethoxy)phenyl)thiophene-2-carboxamide; 3-(Quinolin-4-ylmethylamino)-N-(4-(trifluoromethoxy)phenyl)thiophene-2-carboxamide; 3-(Quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide; 3-[ (Quinolin-4-ylmethyl)amino]-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide; 3-[ (4-Quinolinylmethyl)amino]-N-[4-(trifluoromethoxy)phenyl]-2-thiophenecarboxamide; N-(4-Trifluoromethoxyphenyl)3-( (quinolin-4-ylmethyl)amino)thiophene-2-carboxamide
CAS No.:
728033-96-3
Compound CID:
9868037
Formula:
C22H16F3N3O2S
Formula Weight:
443.44
Specification
Targets & IC50:
CSF1R: 15 nM; FLK1: 8 nM; KDR: 9 nM; C-Raf: 41 nM; Lck: 22 nM
Relative Density:
1.450 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
OSI-930 can be used for drug development for tumor-related diseases.
Library Information
Targets:
CSF-1R; Src; c-Kit; Apoptosis; Raf; c-Fms; VEGFR; FLT
Receptors:
Apoptosis; c-Fms; c-Kit; C-Raf; CSF-1R; FLT1; Lck; VEGFR; VEGFR2 (KDR)
Pathways:
Apoptosis; Angiogenesis; MAPK; Tyrosine kinase/adaptors
Plate Number:
AOCL-10
Plate Location:
h4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
82 mg/mL; 184.9 mM
Ethanol Max Solubility:
3 mg/mL; 6.76 mM
ALogP:
6.266
HBA_Count:
3
HBD_Count:
2
Rotatable Bond:
7
